Glycemic control target for liver and cardiovascular events risk in metabolic dysfunction-associated steatotic liver disease.
Nobuharu TamakiShun-Ichi WakabayashiTakefumi KimuraYutaka YasuiKaoru TsuchiyaHiroyuki NakanishiDaniel Q HuangTakeji UmemuraMasayuki KurosakiNamiki IzumiPublished in: Hepatology research : the official journal of the Japan Society of Hepatology (2024)
The risk of liver-related events as well as MACE increased in a dose-dependent fashion with an increase in HbA1c levels, except for patients with HbA1c <5.0% for liver-related events. An HbA1c level of 7% was the optimal threshold associated with a lower risk of complications and may be utilized as a target for glycemic control in patients with MASLD.